Between 2018 and 2023, Dr Ivan Puah treated over 550 cases, addressing unique challenges in Singapore's multi-ethnic population. His study included diverse case profiles....
VANCOUVER, BC and LAS VEGAS, June 2, 2026 /CNW/ - Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a...
Collaboration aims to expand access to Mayo Clinic's trusted healthcare expertise and improve patient and clinician experiences ROCHESTER, Minn., and REDMOND, Wash., June 2, 2026 /PRNewswire/...
Revenue increased 449% year-over-year while the Company continued to scale its healthcare infrastructure platform. VANCOUVER, BC and LAS VEGAS, June 1, 2026 /CNW/ - Hydreight...
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).
SARASOTA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced second quarter 2025 financial results.
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL
NEW YORK, Aug. 13, 2025 /PRNewswire/ -- HopeAI , a Mayo Clinic Platform Accelerate company, is advancing how cancer clinical trials are designed and...
NEW YORK, Aug. 12, 2025 /PRNewswire/ -- HopeAI, an emerging leader in applying artificial intelligence (AI) to accelerate new drug development, has officially joined...
Entered into secured credit agreement with Innoviva for $15 million maturing in 2029
Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02
LOS...
Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045
SAN JOSE, Calif., Aug. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"...